前列腺导管腺癌12例临床病理分析

Clinical and Pathological Features of Prostatic Ductal Adenocarcinoma: An Analysis of 12 Cases

目的探讨前列腺导管腺癌的临床及病理特征。方法收集前列腺导管腺癌标本12例,将标本进行切片,行HE染色,在光学显微镜下观察病理组织变化。采用EnvisionTM Plus两步法检测12例标本中P504s、PSA、PAP、34βE12、P63及P53的表达情况。结果 12例标本中,5例为混合型前列腺导管腺癌,与腺泡腺癌同时存在,并混杂在一起;7例为单纯前列腺导管腺癌。P504s(+)11例(91.7%),PSA(+)11例(91.7%),PAP(+)10例(83.3%),34βE12(+)5例(41.7%),P63(+)9例(75.0%),P53(+)5例(41.7%)。结论前列腺导管腺癌难于早期诊断,确诊主要依靠病理和免疫组化检查,且预后较差,应按照高危前列腺癌的治疗原则进行治疗。

Objective To explore the clinical and pathological features of prostatic ductal adenocarcinoma.Methods Twelve prostatic ductal adenocarcinoma specimens were sliced and HE staining was performed to observe the pathological changes under the microscope.The expression of P504s,PSA,PAP,34βE12,P63 and P53 was detected by EnvisionTM Plus two-step assay.Results Among the 12 specimens,prostatic ductal adenocarcinoma mixed with acinar adenocarcinoma was found in 5 and pure prostatic ductal adenocarcinoma in 7.Immunohistochemical detection showed P504s（＋）in 11 cases（91.7%）,PSA（＋）in 11 cases（91.7%）,PAP（＋）in 10 cases（83.3%）,34βE12（＋）in 5 cases（41.7%）,P63（＋）in 9 cases（75.0%）and P53（＋）in 5 cases（41.7%）.Conclusion Prostatic ductal adenocarcinoma is difficult to diagnose early.The diagnosis mainly rely on pathological and immunohistochemical examination and the prognosis is poor.The treatment of prostatic ductal adenocarcinoma should be carried out in accordance with the principles of treatment of high-risk prostate cancer.